跳至主要内容
临床试验/NCT01149382
NCT01149382已完成不适用

Humoral Immune Response To Influenza Vaccine In Islet Cell In Transplant Recipients

University of Alberta1 个研究点 分布在 1 个国家目标入组 61 人开始时间: 2010年8月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
61
试验地点
1
主要终点
•Seroprotection rate

研究概览

简要总结

Influenza virus is an important cause of morbidity in the transplant population and can lead to viral and bacterial pneumonia. Although the annual influenza vaccine is recommended for organ transplant patients, studies have shown that the standard inactivated influenza vaccine has poor immunogenicity in this population. The investigators plan to test the humoral response to vaccination and look at HLA upregulation

详细描述

OBJECTIVE AND HYPOTHESIS

  • To test the specific humoral response of the influenza vaccine after islet cell transplantation
  • To test the production of HLA alloantibodies after vaccination.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Adult islet cell transplant recipients
  • Able to provide informed consent

排除标准

  • Egg allergy
  • Previous life-threatening reaction to influenza vaccine (ie Guillain Barre Syndrome)
  • Febrile illness in the past two weeks
  • Unable to provide informed consent

结局指标

主要结局

•Seroprotection rate

时间窗: 3 months

defined as a post-vaccination titer of ≥1:40

次要结局

  • •Seroconversion rate(3 months)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Deepali Kumar

Assistant Professor

University of Alberta

研究点 (1)

Loading locations...

相似试验